No Data
No Data
Here's Why Biomea Fusion, Inc. (NASDAQ:BMEA) Is Among the Best Diabetes Stocks to Buy Under $10
Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Biomea Fusion Advances Diabetes Treatment With Positive Study Results
Truist Financial Maintains Biomea Fusion(BMEA.US) With Buy Rating
A Quick Look at Today's Ratings for Biomea Fusion(BMEA.US), With a Forecast Between $11 to $50
Barclays Remains a Hold on Biomea Fusion (BMEA)